Search

Isoflavone

Soybean is an exceptionally rich source of dietary isoflavones, where the average isoflavone content is 1-2 mg/gram [A33103]. … Isoflavone is found as one of constituents in oral over-the-counter dietary supplements indicated for improved bone mass density and body fat regulation.

Phenothrin

Zucapsaicin

Zucapsaicin was approved by the Health Canada in 2010 as topical cream marketed under the brand name Zuacta but currently not FDA-approved.

Quercus acutissima whole

Quercus acutissima whole is a plant/plant extract used in some OTC (over-the-counter) products. It is not an approved drug.

Dydrogesterone

Unlike many other progestational compounds, dydrogesterone produces no increase in temperature and does not inhibit ovulation.

Anagrelide

[L14153] It is an oral imidazoquinazoline that was first approved for use in the US in 1997.[A214274] It appears to carry a better response rate than other thrombocythemia treatments (e.g. … Anagrelide is a platelet-reducing agent used to lower dangerously elevated platelet levels (i.e. to treat thrombocythemia) in patients with myeloproliferative neoplasms.

Anifrolumab

[A237044] Anifrolumab was granted FDA approval on 30 July 2021.[L34929] … Anifrolumab, or MEDI-546, is a type 1 interferon receptor (IFNAR) inhibiting IgG1κ monoclonal antibody indicated in the treatment of adults with moderate to severe systemic lupus erythematosus.

DA-8031

DA-8031 is under investigation in clinical trial NCT01798667 (Clinical Trial to Evaluate the Efficacy and Safety of DA-8031 in Male Patients With Premature Ejaculation).

Ansuvimab

Infection with pathogenic filoviruses, such as _Zaire ebolavirus_ (Ebola virus, EBOV), can cause severe hemorrhagic fever in humans, resulting in frequent outbreaks with case fatality rates as high as … [A225943, A225948, A226035] A randomized, controlled trial of four investigational therapies for Ebola virus disease (EVD) in the Democratic Republic of Congo during a previous outbreak that began in 2018

Cenobamate

[L10653] Cenobamate was granted FDA approval on 21 November 2019.[L10653] … Cenobamate, or YKP-3089, is an antiepileptic drug developed by SK Pharmaceuticals and used to treat partial onset seizures.